Skip to main content

Peer Review reports

From: Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia

Original Submission
26 Sep 2018 Submitted Original manuscript
3 Nov 2018 Reviewed Reviewer Report - Susan - Branford
7 Jan 2019 Reviewed Reviewer Report - Reviewer 2
22 Feb 2019 Author responded Author comments - Graeme Greenfield
Resubmission - Version 2
22 Feb 2019 Submitted Manuscript version 2
5 Mar 2019 Reviewed Reviewer Report - Susan - Branford
22 Mar 2019 Author responded Author comments - Graeme Greenfield
Resubmission - Version 3
22 Mar 2019 Submitted Manuscript version 3
Publishing
8 Apr 2019 Editorially accepted
2 May 2019 Article published 10.1186/s12878-019-0139-2

You can find further information about peer review here.

Back to article page